Individualizing treatment with verapamil for cluster headache patients

Area of Science:

• Neurology
• Pharmacology

Background:

• Verapamil is a leading prophylactic drug for cluster headaches (CH).
• Standard dosages (240-480 mg/day) show variable efficacy (50-80%).
• Clinical practice suggests individual dose titration is necessary, especially for nocturnal attacks.

Purpose of the Study:

• To determine the minimum effective verapamil dose for preventing episodic and chronic cluster headaches.
• To implement a supervised, individualized dosage adjustment scheme.

Main Methods:

• Consecutive patients with episodic or chronic CH were enrolled.
• A progressive verapamil dosage regimen was initiated and adjusted based on attack diaries and timing.
• Patients were monitored weekly until headache control was achieved.

Main Results:

• Complete headache relief was achieved in 94% of episodic CH and 55% of chronic CH patients.
• Dosages ranged from 200-480 mg for most, with some requiring up to 960 mg.
• Additional therapies were needed for 10 patients with incomplete relief; one patient discontinued due to side effects.

Conclusions:

• Individualized verapamil dosing is highly effective for CH prevention.
• Supervised, progressive dose escalation leads to complete attack suppression in most episodic CH cases.
• While effective, chronic CH management may require additional treatments, with notable gender disparities in response.